Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance ...

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold ...

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...